Relief Therapeutics Holding SA

SWX:RLF Stock Report

Market Cap: CHF 54.6m

Relief Therapeutics Holding Past Earnings Performance

Past criteria checks 0/6

Relief Therapeutics Holding's earnings have been declining at an average annual rate of -48.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 56.3% per year.

Key information

-48.7%

Earnings growth rate

-39.9%

EPS growth rate

Biotechs Industry Growth18.9%
Revenue growth rate56.3%
Return on equity-93.9%
Net Margin-537.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Jan 13
We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Recent updates

We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Oct 09
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too

Sep 03
Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too

Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement

Sep 03
Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05
Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04
Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Jan 13
We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Revenue & Expenses Breakdown

How Relief Therapeutics Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SWX:RLF Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 249-46141
31 Mar 247-72171
31 Dec 236-98191
30 Sep 236-89222
30 Jun 236-81253
31 Mar 236-66258
31 Dec 226-512412
30 Sep 226-492117
30 Jun 227-471921
31 Mar 225-411720
31 Dec 213-351519
30 Sep 212-331221
30 Jun 210-31822
31 Mar 210-19718
31 Dec 200-8514
30 Sep 200-357
30 Jun 200140
31 Mar 200-320
31 Dec 190-710
30 Sep 190-410
30 Jun 191-110
31 Mar 191-110
31 Dec 181010
30 Sep 180-110
30 Jun 180-210
31 Mar 180-310
31 Dec 170-320
30 Sep 170-1020
30 Jun 170-1830
31 Mar 170-1720
31 Dec 160-1720

Quality Earnings: RLF is currently unprofitable.

Growing Profit Margin: RLF is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RLF is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.

Accelerating Growth: Unable to compare RLF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RLF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: RLF has a negative Return on Equity (-93.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexandre MüllerResearch Dynamics
Bob PoolerValuationLAB AG